Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787561 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
A Phase 2 study of Mesonephric Gynecologic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT05787561 is a Phase 2 study of Mesonephric Gynecologic Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT05787561, a Phase 2 study of Mesonephric Gynecologic Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Conditions Studied
Interventions
- DRUG Defactinib
- DRUG Avutometinib (VS-6766)
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05787561
The ClinicalTrials.gov registry entry for NCT05787561 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesonephric Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Defactinib is the first listed.
NCT05787561 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05787561 about?
NCT05787561 is a clinical study titled "A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer". This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
What is the current status of trial NCT05787561?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-03-15. Estimated completion is 2027-03.
What conditions does trial NCT05787561 study?
This clinical trial studies the following conditions: Mesonephric Gynecologic Cancer.
What interventions are being tested in trial NCT05787561?
The interventions under investigation include: Defactinib (DRUG), Avutometinib (VS-6766) (DRUG).
Who is sponsoring clinical trial NCT05787561?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05787561 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.